IG7.F MEMPHASYS LTD

Healthcare Biotechnology Frankfurt Exchange
0.0010 EUR
Close of Nov 12, 2026
0.0010 0.0050
Market cap
EUR 3.10M
P/E
-
P/B
1.19x
ROE
-97.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is IG7.F undervalued?

Graham number

The Graham number of MEMPHASYS LTD cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

MEMPHASYS LTD fundamental analysis

No fundamental analysis for MEMPHASYS LTD yet.

MEMPHASYS LTD stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About MEMPHASYS LTD

Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company offers Felix system, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, an in-vitro diagnostic device; and AI-Port, an ambient temperature semen transport device for artificial insemination in animals. In…

Full company profile